Coronary Artery Disease

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy

Gervasio A. Lamas, MD,[a,j] Robin Boineau, MD, MA,[b,j] Christine Goertz, DC, PhD,[c,j] Daniel B. Mark, MD, MPH,[i,j] Yves Rosenberg, MD,[b,j] Mario Stylianou, PhD,[b,j] Theodore Rozema, MD,[d,j] Richard L. Nahin, PhD, MPH,[e,j] L. Terry Chappell, MD,[f,j] Lauren Lindblad, MS,[i,j] Eldrin F. Lewis, MD,[g,j] Jeanne Drisko, MD,[h,j] and Kerry L. Lee, PhD[i,j] *Miami Beach, FL; Bethesda, MD; Davenport, IA; Landrum, SC; Bluffton, OH; Boston, MA; Kansas City, KS; and Durham, NC*

Background Disodium ethylenediaminetetraacetic acid (EDTA) reduced adverse cardiac outcomes in a factorial trial also testing oral vitamins. This report describes the intent-to-treat comparison of the 4 factorial groups overall and in patients with diabetes.

Methods This was a double-blind, placebo-controlled, 2 × 2 factorial multicenter randomized trial of 1,708 post–myocardial infarction (MI) patients ≥50 years of age and with creatinine ≤2.0 mg/dL randomized to receive 40 EDTA chelation or placebo infusions plus 6 caplets daily of a 28-component multivitamin-multimineral mixture or placebo. The primary end point was a composite of total mortality, MI, stroke, coronary revascularization, or hospitalization for angina.

Results Median age was 65 years, 18% were female, 94% were Caucasian, 37% were diabetic, 83% had prior coronary revascularization, and 73% were on statins. Five-year Kaplan-Meier estimates for the primary end point was 31.9% in the chelation + high-dose vitamin group, 33.7% in the chelation + placebo vitamin group, 36.6% in the placebo infusion + active vitamin group, and 40.2% in the placebo infusions + placebo vitamin group. The reduction in primary end point by double active treatment compared with double placebo was significant (hazard ratio 0.74, 95% CI 0.57-0.95, $P = .016$). In patients with diabetes, the primary end point reduction of double active compared with double placebo was more pronounced (hazard ratio 0.49, 95% CI 0.33-0.75, $P < .001$).

Conclusions In stable post-MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance. (Am Heart J 2014;168:37-44.e5.)

Chelation therapy with ethylenediaminetetraacetic acid (EDTA) has long been used to treat atherosclerotic coronary and peripheral artery disease.[1,2] The Trial to Assess Chelation Therapy (TACT)[3] found that this treatment reduced clinical events in post–myocardial infarction (MI) patients, particularly in patients with diabetes.[4] Chelation therapy is often administered in conjunction with a regimen of oral high-dose vitamins and minerals,[5] notwithstanding that the results of clinical trials of lower-dose vitamin therapy have generally been negative.[6,7] Nonetheless, chelation practitioners argued forcefully during the design phase of TACT for the inclusion of an adjunctive high-dose vitamin and mineral regimen. Thus, a 2 × 2 factorial design (intravenous (IV) chelation vs placebo plus oral vitamins vs placebo) was selected to control for the use of vitamins, study the effects of chelation with versus without high-dose vitamins, and thereby eliminate potential confounding due to uncontrolled vitamin use by study participants.[8]

The clinical safety and efficacy of the TACT vitamin regimen have been reported.[9] These analyses demonstrated

From the [a]The Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, FL, [b]The National Heart, Lung, and Blood Institute, Bethesda, MD, [c]The Palmer Center for Chiropractic Research, Davenport, IA, [d]Biogenesis Medical Center, Landrum, SC, [e]The National Center for Complementary and Alternative Medicine, Bethesda, MD, [f]Celebration of Health Association, Bluffton, OH, [g]Brigham and Women's Hospital and Harvard Medical School, Boston, MA, [h]The University of Kansas Medical Center, Kansas City, KS, and [i]The Duke Clinical Research Institute, Durham, NC

[j] for the TACT Investigators.

Guest Editor: Robert A. Harrington, MD, served as guest editor for this article

Submitted December 19, 2013; accepted February 27, 2014.

Reprint requests: Gervasio A. Lamas, MD, Chief, Columbia University Division of Cardiology, Mount Sinai Medical Center, 4300 Alton Rd, Miami Beach, FL 33140.

E-mail: gervasio.lamas@msmc.com

0002-8703

http://dx.doi.org/10.1016/j.ahj.2014.02.012

a nonsignificant 11% reduction in the risk of the primary combined end point. The purpose of this paper is to describe the results across the 4 factorial groups in the 1,708 randomized patients and among the 633 with diabetes.

Methods

Overview

TACT, ClinicalTrials.gov identifier NCT00044213, was a double-blind 2 × 2 factorial trial in which patients were randomized to 4 groups:

1. Active IV chelation infusions + active oral vitamins
2. Active IV chelation infusions + placebo oral vitamins
3. Placebo IV chelation infusions + active oral vitamins
4. Placebo IV chelation infusions + placebo oral vitamins

The design and organizational aspects of TACT have been published previously.[8] The National Heart, Lung, and Blood Institute, grant U01 HL92607, and the National Center for Complementary and Alternative Medicine, grant U01 AT001156, provided funding and oversight to support the research and creation of the paper. The institutional review board at each clinical site approved the study, and patients provided written informed consent. A Data and Safety Monitoring Board monitored the study. The authors are solely responsible for the design and conduct of the study, all study analyses, the drafting and editing of the paper, and its final contents.

Study population

Patients were ≥50 years of age and had sustained an MI ≥6 weeks prior to enrollment. Patients were ineligible if they were women of childbearing potential, had a serum creatinine >2.0 mg/dL, or had other exclusion criteria as previously reported.[8] Patients were enrolled at a total of 134 sites in the United States and Canada.

Subgroup with diabetes

The study protocol called for examination of various prespecified subgroups, diabetes among them. Therefore, we also report exploratory analyses of the 4 factorial groups in patients with diabetes.

Treatment

The contents of the preparation and administration of the EDTA and placebo EDTA infusion treatments used in TACT have been described[8] (online Appendix Supplementary Table I). Intravenous treatment consisted of 40 infusions of disodium EDTA-based chelation therapy or a normal saline placebo administered as 30 weekly infusions followed by 10 maintenance infusions 2 to 8 weeks apart. The active oral high-dose vitamin treatment was a 28-component mixture to be taken as 3 caplets twice daily until the end of follow-up.

The components and dosing of the oral vitamins were developed with the assistance of chelation practitioners to reflect their standard practice (online Appendix Supplementary Table II).

Follow-up

Patients were seen at baseline and at each chelation infusion visit. Following the infusion phase, patients were called quarterly, attended annual clinic visits, and were seen at the end of the trial or at the 5-year follow-up, whichever was first. Vitamin/placebo caplets were distributed on a 3- to 6-month basis. Unused pills were returned to the site to assess compliance.

End points

The primary end point was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina. The composite of cardiovascular death, reinfarction, or stroke was a prespecified key secondary end point. A blinded independent clinical events committee adjudicated all nonprocedural components of the primary end point. The Data Coordinating Center verified the occurrence of coronary revascularizations using patient medical records.

Safety

Safety monitoring included periodic physical examination and laboratory assessments. A masked Medical Monitor at the Data Coordinating Center reviewed all serious adverse events.

Prespecified subgroups

TACT prespecified several subgroups for analyses. The present report restricts itself to an analysis of the factorial groups in patients with diabetes prior to randomization, as previously defined.[4]

Statistical analysis

As previously reported,[3] TACT enrolled 1,708 patients, with a length of follow-up selected to provide 85% power for detecting a 25% relative reduction in the primary end point for each treatment factor, assuming a 2.5-year event rate in the placebo arm of 20% and a significance level of .05.

The TACT statistical analysis plan prespecified that the factorial groups would be analyzed for the overall study to assess any interaction of chelation therapy with oral vitamins. The analysis of the 4 factorial groups in the diabetes subgroup was not pre-specified and, as such, should be considered an exploratory analysis.

Randomization and treatment comparisons have been previously described.[3]The log-rank test[10] was used for the statistical comparison of treatment groups. Cumulative event rates were calculated according to

Table I. Baseline characteristics of patients for all 4 factorial groups

	EDTA chelation and high-dose vitamins (n = 421)	EDTA chelation and placebo vitamins (n = 418)	Placebo infusions and high-dose vitamins (n = 432)	Placebo infusions and placebo vitamins (n = 437)
Demographics				
Age (y)	64.9 (58.8-71.4)	65.2 (59.7-71.6)	65.6 (58.7-72.2)	65.5 (59.2-71.9)
Female	70 (17%)	82 (20%)	77 (18%)	70 (16%)
White	397 (94%)	393 (94%)	400 (93%)	415 (95%)
BMI	29.2 (26.5-33.4)	30.0 (26.6-33.9)	29.7 (25.9-33.4)	29.9 (27.0-33.8)
Blood pressure				
Systolic	130.0 (118.0-140.0)	130.0 (120.0-140.0)	130.0 (119.0-140.0)	130.0 (120.0-140.0)
Diastolic	76.0 (70.0-80.0)	76.0 (70.0-80.0)	76.0 (68.0-82.0)	76.0 (70.0-80.0)
History				
Hypercholesterolemia	337 (81%)	339 (83%)	343 (81%)	351 (82%)
Hypertension	280 (67%)	288 (69%)	294 (68%)	307 (70%)
Former cigarette smoker	236 (56%)	231 (55%)	251 (58%)	237 (54%)
Angina pectoris	226 (54%)	235 (56%)	221 (51%)	244 (56%)
Anterior MI	174 (41%)	163 (39%)	167 (39%)	170 (39%)
Diabetes	159 (38%)	163 (39%)	164 (38%)	147 (34%)
Congestive heart failure	68 (16%)	86 (21%)	69 (16%)	84 (19%)
Peripheral vascular disease	60 (14%)	66 (16%)	65 (15%)	77 (18%)
Stroke	28 (7%)	29 (7%)	28 (6%)	26 (6%)
Time from qualifying MI to randomization (y)*	4.3 (1.7-9.0)	4.3 (1.8-9.3)	4.8 (1.4-10.2)	4.8 (1.6-8.5)
NYHA functional class				
No heart failure or class I	389 (92%)	375 (90%)	397 (92%)	398 (91%)
Coronary revascularization				
Either CABG or PCI	350 (83%)	344 (82%)	355 (82%)	365 (84%)
PCI	238 (57%)	253 (61%)	246 (57%)	270 (62%)
CABG	198 (47%)	186 (44%)	192 (44%)	198 (45%)
Concomitant medications				
Aspirin, warfarin, or clopidogrel	386 (93%)	382 (92%)	395 (91%)	389 (89%)
Aspirin*	365 (87%)	352 (84%)	364 (84%)	346 (79%)
β-Blocker	293 (70%)	318 (76%)	309 (72%)	306 (70%)
Statin	310 (74%)	305 (73%)	319 (74%)	314 (72%)
ACE or ARB	256 (61%)	269 (64%)	273 (63%)	286 (65%)
Clopidogrel	101 (25%)	111 (28%)	99 (24%)	114 (27%)
Warfarin	28 (7%)	45 (11%)	32 (8%)	43 (10%)
Diabetes medication				
Oral hypoglycemic	103 (25%)	88 (22%)	104 (25%)	85 (20%)
Insulin*	25 (6%)	48 (12%)	46 (11%)	41 (10%)
Laboratory examinations				
Total cholesterol (mg/dL)	164.0 (139.0-193.0)	161.5 (141.0-192.0)	163.5 (141.5-194.0)	169.0 (144.0-202.5)
Triglycerides (mg/dL)	138.0 (99.0-203.0)	131.0 (91.0-193.0)	145.0 (101.0-206.0)	147.0 (99.0-210.0)
Glucose (mg/dL)	103.0 (92.0-120.0)	102.5 (92.0-123.0)	102.0 (91.0-124.0)	103.0 (93.0-119.0)
LDL (mg/dL)	88.0 (66.5-113.5)	86.0 (66.0-111.0)	87.5 (66.0-112.5)	93.0 (71.0-122.0)
HDL (mg/dL)	43.0 (36.0-52.0)	43.0 (36.4-52.0)	43.0 (37.0-51.0)	41.0 (36.0-50.0)
Creatinine (mg/dL)	1.1 (0.9-1.2)	1.1 (0.9-1.2)	1.1 (0.9-1.2)	1.1 (0.9-1.2)

* $P < .05$.

the Kaplan-Meier method.[11] Relative risks were expressed as hazard ratios (HRs) with associated confidence intervals (CIs) and were calculated using the Cox proportional hazards model.[12] Outcomes were compared across the factorial groups, both in the overall population as well as for the population of patients with diabetes. Comparisons of treatment groups with respect to adherence and safety were performed using the χ^2 test. Continuous variables are expressed as medians and interquartile ranges unless otherwise specified. Statistical analyses were performed using SAS software, versions 8.2 and 9.2 (SAS Institute, Cary NC).

Results

Between September 10, 2003, and October 4, 2010, 1,708 patients were randomized: 421 to EDTA chelation infusions + high-dose oral multivitamins, 418 to EDTA chelation infusions + oral placebo, 432 to placebo infusions + high-dose oral multivitamins, and 437 to placebo infusions + oral

Figure 1



A, Kaplan-Meier curves (4 factorial groups, primary end point). **B**, Kaplan-Meier curves placebo/placebo versus active/active (primary end point).

placebo. The median duration of follow-up was 55 months (interquartile range, 26-60) overall. There was no significant difference in length of follow-up across all 4 groups.

Baseline characteristics

Baseline characteristics were similar among the 4 randomized factorial groups (Table I). Patients were 65

Table II. Primary and secondary end point components for all 4 factorial groups

	EDTA chelation and high-dose vitamins (n = 421)	EDTA chelation and placebo vitamins (n = 418)	Placebo infusions and high-dose vitamins (n = 432)	Placebo infusions and placebo vitamins (n = 437)	P*
Primary end point					
All-cause mortality, MI, stroke, coronary revascularization, or hospitalization for angina	108 (26%)	114 (27%)	122 (28%)	139 (32%)	.016
Death	43 (10%)	44 (11%)	44 (10%)	49 (11%)	.490
MI	23 (5%)	29 (7%)	35 (8%)	32 (7%)	.207
Stroke	4 (1%)	6 (1%)	4 (1%)	9 (2%)	.161
Coronary revascularization	60 (14%)	70 (17%)	72 (17%)	85 (19%)	.017
Hospitalization for angina	6 (1%)	7 (2%)	6 (1%)	12 (3%)	.147
Secondary end point					
Cardiovascular death, MI, or stroke	39 (9%)	57 (14%)	55 (13%)	58 (13%)	.045
Cardiovascular death	19 (5%)	31 (7%)	26 (6%)	25 (6%)	.355

Log-rank 1 *df P* values. This is a comparison of the active-active versus placebo-placebo cells only.

(59-72) years old, 18% were female, and 9% were minorities. The qualifying MI had occurred 4.6 (1.6-9.2) years prior to enrollment. There was a high prevalence of diabetes (37%); prior coronary revascularizations (83%); and postinfarct, guideline-recommended medication use of aspirin (84%), β-blocker (72%), and statin (73%).

Factorial treatment comparisons (overall group)

The 5-year Kaplan-Meier event rate estimate for the primary end point was 31.9% in the chelation + high-dose vitamin group, 33.7% in the chelation + placebo vitamin group, 36.6% in the placebo infusion + active vitamin group, and 40.2% in the placebo infusions + placebo vitamin group (Figure 1, *A*; Table II). The primary end point by treatment group occurred in 139 (32%) of the placebo infusion + placebo vitamin group and 108 (26%) of patients in the chelation + high-dose vitamin group (Figure 1, *B*). The groups with one active therapy had an intermediate number of events and were not statistically significantly different from the placebo-placebo group. The comparison of active infusion + active vitamins with placebo infusions + placebo vitamins was significant (HR 0.74, 95% CI 0.57-0.95, $P = .016$). The absolute difference in 5-year Kaplan-Meier estimated event rates between placebo-placebo and active-active groups was 8.3%, and the number needed to treat (NNT) to prevent 1 event over 5 years was 12.

The principal secondary end point, cardiovascular death, MI, or stroke, occurred in 58 (13%) of the placebo infusions + placebo vitamin group, 57 (14%) of the chelation + placebo vitamin group, 55 (13%) of the placebo infusion + active vitamin group, and 39 (9%) of patients in the chelation + high-dose vitamin group. The comparison of active infusion + active vitamins with placebo infusions + placebo vitamins favored chelation + vitamins (HR 0.66, 95% CI 0.44-0.99, $P = .046$). The groups with one active therapy had an intermediate number of events and were not statistically significantly different from the placebo-placebo group.

Treatment adherence

There were no significant differences in adherence to IV infusions or to oral vitamins between groups (Table III). Consent withdrawal at some point during the trial was reported in 289 patients. A greater frequency of consent withdrawals occurred among patients randomized to placebo infusions.

Safety

Serious adverse events were documented in 55 patients (13%) of the EDTA chelation and high-dose vitamin group, 45 (11%) of the EDTA chelation and placebo vitamin group, 69 (16%) of the placebo infusion and high-dose vitamin group, and 58 (13%) of the placebo infusion and placebo vitamin group ($P = .170$).

Diabetes analyses

In the 633 patients with diabetes, the 5-year Kaplan-Meier event rate estimates for the primary end point was 29.1% in the chelation + high-dose vitamin group, 36.1% in the chelation + placebo vitamin group, 48.1% in the placebo infusion + active vitamin group, and 47.3% in the placebo infusions + placebo vitamin group (Figure 2, *A*). The primary end point by treatment group occurred in 56 (38%) of the placebo infusion + placebo vitamin group and 36 (23%) of patients in the chelation + high-dose vitamin group (HR 0.49, 95% CI 0.33-0.75, $P < .001$, 5-year NNT = 5.5) (Figure 2, *B*). The factorial groups receiving only one active treatment had intermediate treatment benefit not statistically significantly different from double placebo.

Table III. Patient status by all treatment arms

	EDTA chelation and high-dose vitamins (n = 421)	EDTA chelation and placebo vitamins (n = 418)	Placebo infusions and high-dose vitamins (n = 432)	Placebo infusions and placebo vitamins (n = 437)	*P*
Patient status					
Number of infusions	40 (32-40)	40 (31-40)	40 (26-40)	40 (30-40)	.401
Discontinued infusions	114 (27%)	119 (28%)	146 (34%)	135 (31%)	.152
Completed 30 infusions	324 (77%)	323 (77%)	319 (74%)	329 (75%)	.622
Completed 40 infusions	283 (67%)	282 (67%)	267 (62%)	285 (65%)	.275
Discontinued vitamins	185 (44%)	185 (44%)	209 (48%)	205 (47%)	.503
Continued vitamins for at least 1 y	328 (78%)	321 (77%)	317 (73%)	325 (74%)	.384
Continued vitamins for at least 3 y	210 (50%)	216 (52%)	190 (44%)	210 (48%)	.135
Consent withdrawal	50 (12%)	65 (16%)	91 (21%)	83 (19%)	.002

Discussion

TACT was designed as a factorial trial of IV EDTA-based chelation and high-dose oral vitamins to reflect chelation practice in the community and control for confounding. Thus, we performed an analysis of the 4 groups of the factorial treatment allocation. The analyses demonstrated a stepwise gradient in benefit, with highest risk accrued by patients on standard post-MI care, but neither chelation nor vitamins; intermediate risk by patients receiving only one intervention; and lowest risk by patients receiving both chelation and vitamins. When compared with patients receiving placebo only, the HR of patients receiving both the study interventions was 0.74 (95% CI 0.57-0.95, P = .016), with a 5-year NNT for the primary end point of 12. This compares with the 5-year NNT of 16 for statin therapy for secondary prevention.[13] These effects were observed against a background of modern, evidence-based treatments for post-MI patients, including statins in 73% of patients, with a median low-density lipoprotein cholesterol of 89 mg/dL. Moreover, the benefit of combined therapy in patients with diabetes was greater, with a 5-year NNT for the primary end point of 5.5, again with a background of statin therapy in 76% of the diabetic patients.

Others have reported epidemiological[14–16] and experimental findings[17–19] that may explain benefits of metal chelation in cardiovascular disease. Lead and cadmium are associated with MI, stroke, hypertension, and death. Mechanisms include individual toxicities for each metal ion, but also a class-specific action on the body's defenses against oxidant stress. EDTA chelates environmental contaminants like lead, cadmium, antimony, tungsten, and many others.[20] In diabetic patients, copper and iron, both chelated by EDTA, are tightly linked to nonenzymatic catalytic oxidation of glucose, leading to the formation of advanced glycation end products. Other metals,[21] also chelated by EDTA, may be involved with these redox reactions in diabetic patients, accounting for yet another mechanism of action for EDTA. The xenobiotic metal hypothesis is particularly appealing because the clinical benefits of chelation persist even after the infusions stop, with continued late separation of event curves.

There are other potential explanations for the observed treatment effect. The chelation solution contains a high dose of vitamin C, an antioxidant vitamin that may help reverse some forms of endothelial dysfunction.[22] Whether repetitive infusions of vitamin C could lead to the persistent effect observed in TACT after infusions stop, however, seems doubtful.

Vitamin therapy has been exhaustively studied in clinical trials as primary prevention for coronary disease. Those trials, which have largely failed to detect any evidence of a treatment benefit, have almost all used one or a small number of single vitamins at modest doses.[7,23] Thus, the lack of benefit of oral vitamins and minerals on cardiovascular events in prior studies should be recognized as pertaining to a different regimen than the high-dose oral multivitamin and mineral regimen used here and a different (primary vs secondary prevention) study population.

The incremental benefit observed in the vitamin + chelation group calls for a methodological explanation. We reported that there was a nonsignificant 11% reduction in the point estimate of the primary end point with oral vitamin therapy.[9] Our trial was not powered to detect an 11% difference between groups with sufficient precision to exclude the null effect. This small benefit of oral vitamin therapy, although not statistically significant by itself, may explain the incremental reduction in HR, from 0.82^3 to 0.74, we observed when patients receiving both active treatments were compared to the double placebo patients. A similar explanation applies to the large benefit observed in patients with diabetes treated with the double active regimen, compared with the double placebo.

Study caveats

Given the unexpected findings of TACT for practitioners of cardiovascular medicine, establishing the clinical and scientific significance of the TACT findings will require the performance of additional (ie, more than one) high-quality, adequately powered clinical trials, along with relevant laboratory studies to help identify mechanisms of benefit.

Figure 2



A, Kaplan-Meier curves (4 factorial groups, primary end point, diabetes). **B**, Kaplan-Meier curves placebo/placebo versus active/active (primary end point, diabetes).

Noncompliance with randomized treatment likely reduced the power of the study to discern a difference between groups. The compliance issues have been reviewed in detail in prior publications, and the significance of chelation therapy benefit was maintained in conservative sensitivity analyses.[3,4] In addition, all patients had their

death index status checked at the end of the study; and some patients withdrew after having sustained a primary end point, which mitigates some loss of data.

Conclusions

In stable post-MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance.

Disclaimer

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Heart, Lung, and Blood Institute; the National Center for Complementary and Alternative Medicine; or the National Institutes of Health.

Acknowledgements

The authors gratefully acknowledge the organizational skills of Ana Mon, MPH Project Leader at the Clinical Coordinating Center; Alyssa Cotler at the National Center for Complementary and Alternative Medicine; Susan Dambrauskas (formerly at National Heart, Lung, and Blood Institute) and Vivian Thompson at the DCRI for their competent professional assistance; and the Florida Heart Research Institute for supporting the pilot study. Gervasio Lamas, MD, reports that, from 2000 to 2003, he served as a consultant to OmniComm, the electronic data capture company used in the trial. No funds were received, and all ties were severed as of 09/10/2003. The authors have no other conflicts to report.

References

1. Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci 1956;232(6):654-66.
2. Grier MT, Meyers DG. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 1993;27:1504-9.
3. Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA 2013;309(12):1241-50.
4. Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes 2014;7:15-24.
5. Rozema T.C. Special issue: protocols for chelation therapy. J Adv Med. 1997;10:5-100.
6. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. J Am Med Assoc 2007;297(8):842-57.
7. Sasso HD, Christen WG, Bubes V, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012;308 (17):1751-60.
8. Lamas GA, Goertz C, Boineau R, et al. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J 2012;163(1): 7-12.
9. Lamas G, Boineau R, Goertz C, et al. Oral high-dose multivitamins and minerals after myocardial infarction. A randomized, controlled trial. Ann Intern Med 2013;159:797-804.
10. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. New York: John Wiley & Sons, Inc. 2002.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
12. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972;34:187-220.
13. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled, trials. BMJ 2006;332: 1115-24.
14. Tellez-Plaza M, Guallar E, Fabsitz RR, et al. Cadmium exposure and incident peripheral arterial disease. Circ Cardiovasc Qual Outcomes 2013;6:626-33.
15. Menke A, Muntner P, Batuman VV, et al. Blood lead below 0.48 μmol/L (10 μg/dL) and mortality among US adults. Circulation 2006;114(13):1388-94.
16. Nawrot TS, Staessen JA. Low-level environmental exposure to lead unmasked as silent killer. Circulation 2006;114: 1347-9.
17. Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest 2001;107: 799-801.
18. Nagai R, Murray DB, Metz TO, et al. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012;61:549-59.
19. Frizzell N, Baynes JW. Chelation therapy: overlooked in the treatment and prevention of diabetes complications? Future Med Chem 2013;5:1075-8.
20. Cranton EM, Liu ZX, Smith IM. Urinary trace and toxic elements and minerals in untimed urine specimens. Textbook on EDTA chelation therapy. 2nd ed. Charlottesville, VA: Hampton Roads Publishing Co.; 2001. p. 503-39.
21. Agarwal S, Zaman T, Tuzcu EM, Kapadia SR. Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999-2006. Angiology 2011;62(5):422-9.
22. Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93(6):1107-13.
23. Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003-2006. J Nutr 2011;141:261-6.

Appendix. TACT investigators, leadership, and trial committees

In addition to the authors, the following Investigators and Coordinators participated in the Trial to Assess Chelation Therapy.

United States

Bronx-Lebanon Hospital Center: Bhalodkar, Narendra, Noneta Montinola; Magaziner Center for Wellness: Allan Magaziner, Betty Ann Persico; The Ohio State University Medical Center: Raymond Magorien, Luba Mazanec; The Johns Hopkins University: Pamela Ouyang, Jeanne Wingo; Baystate Medical Center:Mara Slawsky, Judith Fleurent; Heart Care Center: Russell Silverman, Sherri Loucks; Androscoggin Cardiology Associates: Robert Weiss, Diana Cass; Family Health Medical Services: Robert Berke, Paige Davidson; Main Line Health Heart Center: Robert Bulgarelli, Susan Herring; New York VA, Cardiovascular Clinical Research Center: Steven Sedlis, Estelita Anteola; University Hospitals of Cleveland: Austin Halle, Lian Yang; The Institute of Integrative Medicine: Majid Ali, Mahboobullah Baig; Deborah Heart and Lung Center: Alexander Poulathas, Linda Dewey; New York University, School of Medicine:Harmony Reynolds, Chao Wang; Rhinebeck Health Center: Kenneth Bock, Debbie Truin; Schachter Center for Complementary Medicine: Michael Schachter, Sally Minniefield; Dr Yulius Poplyansky: Yulius Poplyansky, Marjorie Patino; Stockton Family Practice: Stuart Freedenfeld, Verna Good; Hudson Valley Heart Center: Glenn Gerber, Patricia O'Brien; Celebration of Health Association: Terry Chappell, Marcia Arnold; Wholistic Health Center: Ralph Miranda, Barb Casella; Staten Island Heart: James Lafferty, Lenora Tafuri-Acevedo; Marino Center for Integrative Medicine: Guy Pugh, Vivian Cole; Land Clinical Studies: James Garofalo, Krystle Chavez; Comprehensive Heart Care: James Roberts, Debra Braun; Advanced Family Medicine: James Johnson, Rosemary Stevenson; Longevity Medical, PA: Ivan Krohn, Lewis S Korb, Lake Cable Medical Center: Jack Slingluff, John Mountford; Woodlands Healing Research: Robert Schmidt, Evelyn Alentin; Matrix Clinic: Lisa Lichota, Keith Rost; Maine Integrative Wellness: Sean McCloy; Upper Valley Family Care: Richard Plumb, Lynn Shough; Arkansas Center for Physical Medicine and Rehabilitation: Linda Bunch, April Archey; Riverside Family Medical: Lisa Merritt, Lisa Lockett; Florida Cardiovascular Group: Steven Borzak, Dina Herig; University of Arkansas for Medical Sciences: Joseph Bissett, Sandra McLaren; Central Arkansas Veterans Healthcare System: Joseph Bissett, Sharon Locke; The Heart Group: Joseph O'Bryan, Mary Barr; Boice Willis Clinic: Shalendra Varma; Cardiology Consultants of South Florida: Ricky Schneider, Rochelle Mckenzie; Complementary Medical Services: James Carter, Kaylynn LeBlanc; Athens Surgery Clinic: Joseph Holliday, Vivian Holliday; Biogenesis Medical Center: Theodore Rozema, Dolly Corbin; Mount Sinai Medical Center: Robert Ciccia-Maclean, Pablo Guala; Mount Sinai Medical Center of Florida: Todd Heimowitz, Helen Garcia; Caring Cardiology: Roy Heilbron, Celia Heilbron; Pain and Healing Center: Angelique Hart; Baptist Cardiac and Vascular Institute: Barry Katzen, Ivette Cruz; Advantage Health Center, LLC: Donald Tice; Wellness and Longevity Center of Louisiana: Sangeeta Shah, Debbie Vige; Virginia Beach General Hospital: John Griffin, Pam Hollsten; Jack Young, MD: Jack Young, Estela Fransbergen; Tru Med: Rajiv Chandra, Terry Murphy; Mark O'Neil Speight, MD: Mark Speight, Janine Speight; Grace Medical Association: Smart Idemudia, Geneve Gutierrez; The Cardiovascular Group: Lawrence Miller, Deanna Overbeck; Heart and Vascular Center for Research, Inc: Clayton Bredlau, Amy Heineman; The Blend Institute: Timothy Blend, Helena Williams; Innovative Research of West Florida: Miguel Trevino, Kimberly Mai; Wellness Center: Jose Oblena, Bonita Harris; Chelation Centers of Texas: Dorothy Merritt, Elizabeth Collins; Tyler Total Wellness Center: Pieter deWet, Cindy deWet; Jenks Health Team: Gerald Wootan, Susan Shaw; Integrative Medical Associates: Connie Ross, Michelle Simpson; COR Research: Clinton Corder, Clinton, Michael Stout; Wright Health & Wellness Center: Robert Wright, Alma Steffen; Florida Cardiovascular Institute: John Sullebarger, Leona Stewart; Wellness Works: Carol Roberts, Berni McClendon; Life Family Practice Center for Complementary and Alternative Medicine: Nelzon Kraucak, Mariann Haring; Northeast LA Anti-Aging and Wellness Center: Linda Bunch, Shauna Gallien; Tequesta Family Practice: RJ Oenbrink, Joe Militello; Full Circle Medical Center: Charles Adams, Jackie Miles; Family/Complimentary Medicine: Karen Dantin, Laurie McDuff; White:Wilson Medical Center, PA: Leslie Fleischer, Cheri Penas; Pearsall Medical and Bariatrics: Gurney Fields Pearsall, Marina M Pearsall; Mueller Institute For Functional Medicine & Research: Jeffrey Mueller, Jeffrey, BJ West; Louisiana Anti-Aging & Wellness Care: Linda Bunch, Kim Robinson; Hillsboro Family Medicine: Paul Kotturan, Nalini Reddy; The Castle Clinic, PLLC: Robert C Allen, Laura Whitaker; Heart Specialists: Rajinder Bhalla, Teresa Hicks; Florida Medical Clinic, PA: Hector Fontanet, Precious Hoyle; Hyperbaric Medicine Inc:Albert Zant, Michelle Potpan; University of Missouri Health Care: Greg Flaker, Sharon Clasby; Henry Ford Health System: Jonathan Ehrman, Matthew Saval; University of Kansas Medical Center: Jeanne Drisko, Elizabeth Schrick; Waters Preventive Medical Center: Robert Waters, Sarah B Chapman; Bircher Chiropractic and Wellness Center: Donald Riemer, Laura Sembach; Preventive Medicine: Varsha Rathod, Heather Moran; Born Preventive Health Care Clinic & Crossroads Healing Arts: Tammy Born, Judy Schneider; Integrative Medicine Center at Schneck Medical Center: Steven Windley, Stephanie Pyle; Mayo Clinic and Foundation Cardiovascular Health Clinic: Gerald Gau, Dawn Shelstad; Berman Center for Outcomes and Clinical Research: Richard Grimm, Mary Perron; Parchment Family Practice:

Eric Born, Julie Ladkrood; The Preventive Medicine Center: Kenneth Ganapini, Venus Barney; West Holt Medical Clinic: Robert Randall, Teresa Kohle; Northwest Indiana Cardiovascular Physicians Inc: Hector Marchand, Cheryl Kwiatkowski; Cardiovascular Research Foundation: Anita Arnold, Dana Kappel; Care Foundation Inc: Timothy Logeman, Karen Olson; The Center for the Improvement of Human Functioning International: Ron Hunninghake, Mavis Schultz; Brian Dieterle MD, PhD, Internal Medicine: Brian Dieterle, Debra Louderback; Marjon Fariba: Marjon Fariba, Sepideh Arvin Matthew; Hope Medical Holistic Clinic: Zbigniew Grudzien, Marinela Matei; Coyote Healing Center Integrative Medicine and Psychiatry: Richard Dexter, Christine Rupley; ACT/Cardiovascular Research Institute: Ronald Karlsberg, Tracey S Gerez; Patrick A Golden: Patrick Golden, Kathy Sasser; Aurora Denver Cardiology Associates: Nampalli Vijay, Melinda Washam; Casdorph Clinic: Richard Casdorph, Heather Browning; Chris Hatlestad, MD, PC: Chris Hatlestad, Christine Ohlemann; Alaska Cardiovascular Research Foundation: Paul Peterson, Lori Heaney; Scripps Center for Integrative Medicine: Erminia Guarneri, Eva Stuart; Frontier Medical Institute: Terry Grossman, Kathryn Bottinell; Cardiac Solutions: Vishal Patel, Denise Wells; Freedom Center for Advanced Medicine: William David Voss, Lorna Gordon; Gordon Medical Associates: Eric Gordon, Win Bertrand; Phoenix Wellness Group: Eleanor Hynote, Katie Lacey; The Center for Optimal Health: Ann McCombs, Arlene Sellereite; Center for Environmental Medicine: Chris Hatlestad, Cambor Wade; St Charles Health System: Bruce McLellan, Noura Sall.

Canada

Seekers Centre for Integrative Medicine: Richard Nahas (Country Leader), Shadi Nahas; Anti-Aging & Family Wellness Clinic: Arun Dosaj, Diane Dosaj; Chelox: Shmuel Bergman, Mary Toro; The Wellness Centre: Ben Boucher, Robyn Whitty; Jaconello Health Centre: Paul Jaconello, Hildegard Beath; Markham Integrative Medicine: John Gannage, Tony Estacio; Chelation & Natural Therapy, Chelation Center of Don Valley Inc, Chelation Center of Barrie, Inc: Fred Hui, Eva Pacaba; Saskatoon Chelation Centre: Edward Nykiforuk, Val Kalyn; Dr Clare Minielly: Clare Minielly; Recherche Cardiologie Hôtel-Dieu du CHUM: François Reeves; North Bay Complementary: Jean Aubry, Barbara Brooks; Montreal Heart Institute: Jean-Claude Tardif, Randa Zamrini; Cline Medical Centre: John Cline, Frank Pluta.

Data and Safety Monitoring Board: Howard Hodis (Chair), Steven Buckley, Barry R Davis, Theodore Ganiats, Gail Geller, Robert Nash, George Wyse.

Committees and Coordinating Centers

Clinical Events Committee at the Brigham & Women's Hospital: Marc Pfeffer, Eldrin Lewis, Chau Duong, Renée Mercier.

Data Coordinating Center at the Duke Clinical Research Institute, Durham, NC: Kerry Lee (Principal Investigator), Sandra Tourt-Uhlig, Joyce Good, Lauren Lindblad, Loren Lytle, Vivian Thompson, Linda Szczech, Gerard Esposito, Meredith Smith, Trevorlyn Haddock, Constance Bardinelli, Wanda Parker, Lindsey Lambe, Cresha Cianciolo, Brian Fox, Emlie Johnson, Mary Molina, Rita Weber, Leslie Williams.

Economics and Quality of Life Coordinating Center at the Duke Clinical Research Institute, Durham, NC: Daniel Mark (Principal Investigator), Nancy Clapp-Channing, Diane Minshall-Liu, Jason Blevins, Kevin Anstrom, David Knight, Thomas Redick, Andrea Davis, Miguel Pena.

Clinical Coordinating Center at Mount Sinai Medical Center, Miami Beach, FL: Gervasio Lamas (Principal Investigator), Ana Mon, Esteban Escolar, Steven Hussein, Pablo Guala, Kayvan Amini, Faisal Shamshad, Jacqueline Arciniega, Jamie Zimmerman, Danielle Hollar, Beatriz Acevedo, Helen Garcia, Adam Williams, Matthew Shields, Renea Moss, Virginia Martini, Parminder Singh, Jewmaull Reed, Maria Salas, Carlos Zamora, Tristan Edwards, Stephanie Escalante, Laura Davila, Rachel Margolis.

(B) Oral low-dose regimen (taken during infusion phase only)

Supplementary Table I. TACT chelation and placebo solution components (A), and low-dose vitamin regimen (B)

(A) Active infusion

Up to 3 g of disodium EDTA*	
2 g of magnesium chloride	To reduce local discomfort and replace losses
100 mg of procaine HCL	To reduce local discomfort
2500 U of heparin	To reduce local phlebitis
7 g of ascorbate	Antioxidant and to achieve isoosmolarity
2 mEq KCl	To replace losses
840 mg sodium bicarbonate	To act as a buffer and reduce discomfort
250 mg pantothenic acid	For antioxidant properties
100 mg of thiamine	For antioxidant properties
100 mg of pyridoxine	To replace chelation losses
QS with sterile water to 500 mL	
Placebo infusion	
500 mL normal saline and 1.2% dextrose	

*The maximum dose of EDTA was 3 g for patients who have at least 60 kg of lean body weight and normal kidney function. Reduction in kidney function and/or lower lean body weight led to a reduction in the total EDTA dose infused.

(B) Oral low-dose regimen (taken during infusion phase only)

Taken once daily	Amount	% Daily value
Vitamin B6 (as pyridoxine hydrochloride)	25 mg	1250%
Zinc (as zinc gluconate)	25 mg	167%
Copper (as copper gluconate)	2 mg	100%
Manganese (as manganese gluconate)	15 mg	750%
Chromium (as chromium picolinate)	50 μg	42%

Supplementary Table II. Comparison of TACT vitamins and mineral regimen with Centrum

Centrum adults			**TACT high-dose regimen**		
Serving size 1 tablet			*Serving size 6 tablets*		
Each tablet contains		% Daily value	Each tablet contains		% Daily value
Vitamin A	3500 IU (29% as β-carotene)	70%	Vitamin A (as fish liver oil and β-carotene)	25,000 IU	500%
Vitamin C	60 mg	100%	Vitamin C (as calcium ascorbate, magnesium ascorbate, and potassium ascorbate)	1200 mg	2000%
Vitamin D	400 IU	100%	Vitamin D_3 (as cholecalciferol)	100 IU	25%
Vitamin E	30 IU	100%	Vitamin E (as D-α tocopheryl succinate and D-α tocopheryl acetate)	400 IU	1333%
Vitamin K	25 µg	31%	Vitamin K_1 (as phytonadione)	60 µg	75%
Thiamin	1.5 mg	100%	Thiamin (vitamin B_1) (as thiamin mononitrate)	100 mg	6667%
Riboflavin	1.7 mg	100%			
Niacin	20 mg	100%	Niacin (as niacinamide and niacin)	200 mg	1000%
Vitamin B6	2 mg	100%	Vitamin B_6 (as pyridoxine hydrochloride)	50 mg	2500%
Folic Acid	400 µg	100%	Folate (as folic acid)	800 µg	200%
Vitamin B12	6 µg	100%	Vitamin B_{12} (as cyanocobalamin)	100 µg	1667%
Biotin	30 µg	10%	Biotin	300 µg	100%
Pantothenic acid	10 mg	100%	Pantothenic acid (as D-calcium pantothenate)	400 mg	4000%
Calcium	200 mg	20%	Calcium (as calcium citrate and calcium ascorbate)	500 mg	50%
Phosphorus	20 mg	2%			
Iodine	150 µg	100%	Iodine (from kelp)	150 µg	100%
Magnesium	50 mg	13%	Magnesium (as magnesium aspartate, ascorbate, and amino acid chelate)	500 mg	125%
Zinc	11 mg	73%	Zinc (as zinc amino acid chelate)	20 mg	133%
Selenium	55 µg	79%	Selenium (as selenium amino acid chelate)	200 µg	286%
Copper	0.5 mg	25%	Copper (as copper amino acid chelate)	2 mg	100%
Manganese	2.3 mg	115%	Manganese (as manganese amino acid chelate)	20 mg	400%
Chromium	35 µg	29%	Chromium (as chromium polynicotinate)	200 µg	167%
Molybdenum	45 µg	60%	Molybdenum (as molybdenum amino acid chelate)	150 µg	200%
Chloride	72 mg	2%			
Potassium	80 mg	2%	Potassium (as potassium aspartate and potassium ascorbate)	99 mg	3%
Boron	75 µg	*	Boron (as boron aspartate and boron citrate)	2 mg	*
Nickel	5 µg	*			
Silicon	2 mg	*			
Tin	10 µg	*			
Vanadium	10 µg	*	Vanadium (as vanadyl sulfate)	39 µg	*
			Citrus bioflavonoids	100 mg	*
			Choline (as choline bitartrate)	150 mg	*
			Inositol	50 mg	*
			Para-amino benzoic acid	50 mg	*
*Daily value not established.			On Centrum, but not on TACT vitamins		

Suggested use: adults—take one tablet daily with food.

Supplementary Table III. Serious adverse events

Events	EDTA chelation and high-dose vitamins (n = 421)	EDTA chelation and placebo vitamins (n = 418)	Placebo infusions and high-dose vitamins (n = 432)	Placebo infusions and placebo vitamins (n = 437)	*P*
Total	55 (13%)	45 (11%)	69 (16%)	58 (13%)	.170
Blood and lymphatic system disorders	0 (0%)	0 (0%)	0 (0%)	0 (0%)	–
Cardiac disorders	18 (4%)	15 (4%)	21 (5%)	18 (4%)	.833
Ear and labyrinth disorders	0 (0%)	0 (0%)	0 (0%)	0 (0%)	–
Eye disorders	0 (0%)	0 (0%)	0 (0%)	0 (0%)	–
Gastrointestinal disorders	8 (2%)	4 (1%)	4 (1%)	8 (2%)	.451
General disorders and administration site conditions	5 (1%)	4 (1%)	8 (2%)	6 (1%)	.708
Hepatobiliary disorders	1 (0%)	2 (0%)	2 (0%)	0 (0%)	.497
Immune system disorders	0 (0%)	0 (0%)	0 (0%)	0 (0%)	–
Infections and infestations	9 (2%)	9 (2%)	7 (2%)	9 (2%)	.937
Injury, poisoning, and procedural complications	3 (1%)	4 (1%)	4 (1%)	3 (1%)	.936
Investigations	2 (0%)	1 (0%)	2 (0%)	1 (0%)	.866
Metabolism and nutrition disorders	0 (0%)	2 (0%)	1 (0%)	1 (0%)	.617
Reproductive system and breast disorders					
Musculoskeletal and connective tissue disorders	3 (1%)	0 (0%)	0 (0%)	2 (0%)	.128
Neoplasms	6 (1%)	1 (0%)	1 (0%)	3 (1%)	.140
Nervous system disorders	4 (1%)	4 (1%)	7 (2%)	3 (1%)	.642
Psychiatric disorders	1 (0%)	0 (0%)	2 (0%)	1 (0%)	.808
Renal and urinary disorders	1 (0%)	3 (1%)	5 (1%)	1 (0%)	.281
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	–
Respiratory, thoracic, and mediastinal disorders	5 (1%)	7 (2%)	13 (3%)	8 (2%)	0.256
Skin and subcutaneous tissue disorders	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0.744
Surgical and medical procedures	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0.245
Vascular disorders	3 (1%)	1 (0%)	3 (1%)	4 (1%)	0.712